Beer H F, Frey L D, Häberli M, Schubiger P A
Radiopharmacy Division, Paul Scherrer Institute, Villigen, Switzerland.
Nucl Med Biol. 1995 Nov;22(8):999-1004. doi: 10.1016/0969-8051(95)02022-5.
After the successful 123I-labelling of Ro 43-0463 the new radiopharmaceutical was tested in animals and humans. Both investigations proved the binding of the labelled compound to cerebral MAO-B. SPECT investigations resulted in an imaging of the MAO-B distribution in the human brain. This prompted us to develop the labelling of this type of MAO-B inhibitor with 18F enabling us to transfer our results to PET.
在成功地将123I标记到Ro 43 - 0463上之后，这种新的放射性药物在动物和人体上进行了测试。两项研究均证明了标记化合物与脑单胺氧化酶B（MAO - B）的结合。单光子发射计算机断层扫描（SPECT）研究实现了人脑MAO - B分布的成像。这促使我们开发用18F标记这种类型的MAO - B抑制剂的方法，以便能够将我们的研究结果应用于正电子发射断层扫描（PET）。
